Kager L, Bielack S
Abteilung für Kinder- und Jugendheilkunde, St. Anna Kinderspital, Medizinische Universität Wien, Wien, Österreich.
Unfallchirurg. 2014 Jun;117(6):517-22. doi: 10.1007/s00113-013-2473-3.
Osteosarcoma and Ewing sarcoma are the most common chemosensitive sarcomas of the bone.
Development in chemotherapeutic concepts as well as current and future treatment strategies in osteosarcoma and Ewing sarcoma are presented.
A PubMed search for "Osteosarcoma" and "Ewing sarcoma" was performed, and pertinent results were summarized.
In both osteosarcoma and Ewing sarcoma, outcomes achieved with multimodal treatment concepts combining conventional chemotherapy and local treatment have reached a plateau of about 70% for 5-year survival rates.
Improved insights into the molecular biology and genetics of the diseases as well as insights into the interactions between sarcoma cells and the micro-environment and the immune system are necessary to identify novel therapeutic targets in bone sarcomas. Because of the rarity of the diseases, multinational cooperation is essential to evaluate novel therapies in prospective randomized trials.
骨肉瘤和尤因肉瘤是最常见的对化疗敏感的骨肉瘤。
介绍骨肉瘤和尤因肉瘤化疗理念的发展以及当前和未来的治疗策略。
在PubMed上搜索“骨肉瘤”和“尤因肉瘤”，并总结相关结果。
在骨肉瘤和尤因肉瘤中，采用传统化疗与局部治疗相结合的多模式治疗理念所取得的疗效，5年生存率已达到约70%的平台期。
深入了解这些疾病的分子生物学和遗传学，以及肉瘤细胞与微环境和免疫系统之间的相互作用，对于确定骨肉瘤的新治疗靶点至关重要。由于这些疾病罕见，跨国合作对于在前瞻性随机试验中评估新疗法至关重要。
